Zobrazeno 1 - 10
of 194
pro vyhledávání: ''
Autor:
Naoki Kamachi, Masahito Nakano, Takashi Niizeki, Takumi Kawaguchi, Takuji Torimura, Shigeo Shimose, Hironori Koga, Yu Noda, Ryoko Kuromatsu, Masatoshi Tanaka, Tomotake Shirono, Shusuke Okamura, Hideki Iwamoto, Akira Kajiwara
Publikováno v:
Oncology. 99:756-765
Background & Aims: Intermediate hepatocellular carcinoma (HCC) treatment has become complicated due to the development of various molecular-targeted agents (MTAs). We aimed to determine whether the administration of MTAs in patients with intermediate
Autor:
Alessandra Rubagotti, Elisa Zanardi, Sandra Salvi, Linda Zinoli, Chiara Boccardo, Antonio Di Meglio
Publikováno v:
Oncology Research and Treatment. 43:362-371
Introduction: Our understanding of the granularity of breast cancer (BC) clinical outcomes by biologic subtype may be impaired by limited study follow-up times. Objective: We evaluated the impact of modern immunohistochemistry (IHC)-based BC subtypes
Autor:
Kausar Suleman, Noha Jastaniyah, Tusneem Elhassan, Wafa Alkhayal, Osama Almalik, Ali Hassan Mushtaq, Adher Al-Sayed, Dahish Ajarim, Emaan Haque, Taher Al-Tweigeri, Ahmed Badran
Publikováno v:
Oncology. 98:168-173
Background:There is a paucity of literature examining the impact of timing of surgery after neoadjuvant chemotherapy. Objective:This study aimed to analyze the impact of the time taken to initiate surgical treatment following completion of neoadjuvan
Publikováno v:
Oncology Research and Treatment. 43:346-353
Introduction: Mammary Paget’s disease (MPD) is a rare cutaneous manifestation. Epidemiologically, more than half of the MPD patients concurrently have underlying invasive ductal carcinoma (MPD-IDC), and their prognosis remains poor despite multimod
Autor:
Eiji Oki, Yojiro Hashiguchi, Shigeki Yamaguchi, Masafumi Tanaka, Eiji Shinto, Naohiro Tomita, Tetsuya Kusumoto, Sachiyo Tada, Tomoko Matsushima, Kazuo Hase, Masaru Morita, Megumi Ishiguro, Mototsugu Shimokawa, Shinobu Ohnuma
Publikováno v:
Oncology. 98:534-541
Introduction: DNA microarrays, such as the consensus molecular subtype (CMS) classification using >600 genes, are used to predict cancer patient prognosis. We recently constructed a simple 55-gene classifier (55GC) system to risk stratify colon cance
Autor:
Xuejiao Wang, Jinghua Xia, Tao Jiang, Lei Wang, Ying Ying Sun, Zhipei Zhang, Yanning Zhang, Lijun Huang, Miaomiao Wen, Sanhu Yang
Publikováno v:
Oncology Research and Treatment. 43:686-693
Background: Some non-small-cell lung cancer (NSCLC) patients are unexpectedly diagnosed with stage IIIA-N2 disease at the time of thoracoscopy or thoracotomy. Because of the limited statistical evidence of induction chemotherapy for these patients, i
Autor:
Yoshikazu Uenosono, Daisuke Matsushita, Yoshiaki Kita, Shigehiro Yanagita, Shoji Natsugoe, Hiroshi Kurahara, Masahiro Noda, Ken Sasaki, Sumiya Ishigami, Keishi Okubo, Takaaki Arigami, Takao Ohtsuka, Shinichiro Mori
Publikováno v:
Oncology. 98:798-806
Objective: Although chemotherapy has been clinically recommended as the initial treatment for patients with peritoneal dissemination of gastric cancer, poor prognosis has been noted among the same patients. However, the prognostic significance of con
Autor:
Xiaohang Chen, Zhengbo Chen, Jialin Du, Jinghua Li, Zhijian Chen, Shuzhen Cong, Zhenwei Zhong, Jiru Yuan, Jian Kuang, Zeyu Wu
Publikováno v:
Oncology Research and Treatment. 43:27-33
Background: Hepatitis B virus infection has been reported to be associated with some kinds of cancer. The aim of this study was to investigate clinicopathological features of papillary thyroid carcinoma (PTC) patients with positive hepatitis B surfac
Autor:
Nikolaus de Gregorio, Amelie de Gregorio, Jens Huober, Thomas Wolfram Paul Friedl, Florian Ebner, Wolfgang Janni, Peter Widschwendter
Publikováno v:
Oncology. 98:91-97
Objective: At the end of the year 2018, a new FIGO classification for cervical cancer was published, mainly revising stage IB and introducing a new stage IIIC, which includes irrespectively of tumor size and local spread all patients with lymph node
Autor:
Chikage Iguchi, Eiichi Shiba, Noriko Fujita, Keiko Inakami, Hitoshi Yamamoto, Tsutomu Kasugai, Takashi Nomura, Tetsu Yanagisawa, Yukie Enomoto, Toyokazu Aono
Publikováno v:
Oncology. 98:35-41
Background: It is unclear for whom new anti-human epidermal growth factor receptor 2 (anti-HER2) agents, such as pertuzumab and T-DM1, should be considered. We investigated prognostic factors before neoadjuvant chemotherapy (NAC) among HER2-positive